Omar Cardona-Garcia, MD
Neurology · Aguadilla, PRNPI 1205858602
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $12,825 of the $16,205 with a category attached, or 79.1%. Amneal Pharmaceuticals LLC accounts for 79.2% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2020 at $6,326 and has fallen 99.3% since, to $44 in 2025. Among neurology clinicians in PR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 41 payments — averaging $395.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amneal Pharmaceuticals LLC$13K
- AbbVie$2K
- Abbott$686
- GSK$74
- PBG Puerto Rico LLC$67
- Novartis$60
- plus $181 from 6 others
What the payments were for
- Consulting fees$2,10713%
- Speaking & faculty fees$12,82579%
- Travel & lodging$6334%
- Food & beverage$6414%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amneal Pharmaceuticals LLC | 16 | $12,833 |
| AbbVie | 5 | $2,304 |
| Abbott | 5 | $686 |
| GSK | 1 | $74 |
| PBG Puerto Rico LLC | 3 | $67 |
| Novartis | 3 | $60 |
| Greenwich Biosciences, Inc. | 1 | $50 |
| Johnson & Johnson | 2 | $37 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $36 |
| Boehringer Ingelheim | 1 | $26 |
| Pfizer Pharmaceuticals LLC | 1 | $19 |
| Sunovion Pharmaceuticals Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$16,205 in reported general payments places this provider in the 90th percentile of 129 neurology providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RytaryCarbidopa/Levodopa | 162 | $137,843 |
| NuplazidPimavanserin Tartrate | 22 | $114,725 |
| AustedoDeutetrabenazine | 16 | $83,902 |
| Nurtec OdtRimegepant Sulfate | 28 | $59,217 |
| Galantamine ErGalantamine Hbr | 597 | $35,681 |
| UbrelvyUbrogepant | 27 | $30,706 |
| Donepezil Hcl | 3,027 | $20,934 |
| NeuproRotigotine | 24 | $20,466 |
| Rivastigmine | 175 | $20,419 |
| Memantine Hcl | 1,618 | $18,743 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 777 | $18,718 |
| GocovriAmantadine Hcl | 11 | $17,915 |
| Levetiracetam | 555 | $10,242 |
| Emgality PenGalcanezumab-Gnlm | 13 | $9,327 |
| Primidone | 476 | $8,981 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide | $12,833 | $140,911195 claims |
| AbbVieUbrelvy, Synthroid | $2,304 | $32,45156 claims |
| NovartisExelon | $60 | $7,64911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 129 neurology providers in Puerto Rico.
Other neurology in Aguadilla
- Iris Acevedo MartyAguadilla$5K
- Angel ChineaGuaynabo$1.7M
- Jose Avila OrnelasCaguas$538K
- Franchesca Fiorito-TorresSan Juan$453K
- Patricia de JesusCaguas$310K
- Mari GarciaSan Juan$138K
- Cristina Cabret-AymatSan Juan$108K
- Gishlaine Alfonso MendezSan Juan$53K
- Laura Surillo-DahdahGuaynabo$31K
- Jessica Abreu-GarciaPonce$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.